pancreas News
-
Beta Bionics Receives FDA Breakthrough Device Designation for the iLet Bionic Pancreas System
Boston, MA -July 1, 2019 - Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world's first fully automated bionic pancreas — today announced that the company has completed a S63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the ...
-
First Home-Use Trial of the iLet Bionic Pancreas System Using Pre-Filled Cartridges of Dasiglucagon Compatible With iLet Has Been Successfully Completed
Boston, MA and Copenhagen, Denmark - June 6,2019 - Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today that a home-use study of dasiglucagon in the iLet Bionic Pancreas System has been successfully completed. Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet® bionic pancreas using ...
-
Encouraging Results From a Pilot Study Testing the Bionic Pancreas in Cystic Fibrosis Related Diabetes Published in the Journal of Cystic Fibrosis.
Boston, MA-December 3,2019- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world's first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) ...
-
Top 5 Israeli innovations of the past decade
The Start-up Nation has made several ground breaking discoveries in the fields of technology, science, and innovation during the past decade.The first artificial pancreas – A potential cure for diabetes? In a possible future cure for diabetes, researchers at Betalin Therapeutics have engineered the first artificial pancreas. It can be inserted underneath the skin, without anesthesia and ...
-
Aspect Biosystems To Present New Data At International Pancreas And Islet Transplant Association (Ipita) Congress 2021
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and ...
-
Israeli Startup Wants to Cure Diabetes by Making Micro-pancreases. It Worked on Mice
Never mind better insulin shots or cell implants for diabetics: Betalin Therapeutics has a unique approach. A young Israeli company that has cured type-1 diabetes in mice and hopes to do the same for humans one day has won the MIXiii Biomed 2017 pharma startup competition, beating dozens of other firms. Just how cured were these mice, exactly? “They were cured of advanced stages of severe ...
-
Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes
Creative Enzymes, a global leader in diagnostic enzyme manufacturing and supply, is dedicated to offering a wide range of enzyme products as well as customized enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. The primary function of the kidney is to eliminate waste and excess ...
-
Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
-
Polyganics Awarded €1.2 Million for Clinical Development of Liver and Pancreas Sealant Patch
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of its Liver and Pancreas Sealant Patch. ...
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
Israeli firm says micro-pancreas to `cure` diabetes ready for UK trials
Exclusive: hopes testing can begin in 2021 on product intended to free people of need for insulin injections An Israeli company claiming to have created a tiny micro-pancreas that can “cure” diabetes for millions of people has said it will submit a request next month for human clinical trials in the UK. Betalin Therapeutics said its “bio-artificial” pancreas aims to ...
-
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical ...
By Camurus AB
-
First Patients Treated in First-in-Human Trial for ACTISEAL – Polyganics’ Innovative Liver and Pancreas Sealant Patch
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing fluid ...
-
Expand Your Diagnostic Capabilities with Vimago HDVI and Save $$$$ Through Section 179 Tax Deduction
Applications HD 3D imaging technology used in the Vimago system provides a solid volume of data, resulting in gapless, non-interpolated imaging data, delivering a 3D map of densities with spatial resolution that is the same in all three dimensions. Hard Tissue Applications: Skulls - sinus, nasal, bulla, ears, brain, oncology, trauma Orthopedics - stifles, elbows, hips, carpus/tarsus, ...
-
NeoTherma Oncology Reports on the Safety and Effectiveness of RF-generated Heat Delivery in Preclinical Animal Studies with the Vectron TTx Thermal Device intended for Treatment of Deep Solid Tumors at Society for Thermal Medicine Annual Meeting
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, reported the results of a pre-clinical porcine study that demonstrated the safe and effective heating of the pancreas with a prototype version of its Vectron TTx device. Key Findings and Conclusions: Safety demonstrated by the absence of injury to skin, internal organs ...
-
NGOs call for EPA pesticide testing to be updated
The US Environmental Protection Agency have come under fire from leading NGOs for its outdated testing program of endocrine-disrupting chemicals. It is feared that the numerous holes in the current programme fail to detect many serious effects on human development. The Environmental Protection Agency is ready to start testing 67 pesticide ingredients for their possible endocrine disruption ...
-
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is being evaluated as a Targeted ...
-
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when ...
-
Polyganics Opens New State-of-the-Art Facility to Drive Growth
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announces its move to a state-of-the art, purpose-built facility on the Zernike Campus, Groningen. The new building will house Polyganics’ research laboratories, manufacturing and packaging facilities, and its offices. The expansion is essential to accommodate ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you